Li, Wu, Zhou, et al. retrospectively analyze 298 hormone-sensitive prostate cancers with FDG/PSMA dual-tracer PET, linking clinical and imaging metrics to treatment responses. Higher whole-body FDG burden predicts shorter survival and more benefit from chemotherapy, while higher lesional PSMA uptake associates with better radiographic response.
